Pluristem Therapeutics Inc. news

   Watch this stock
Showing stories 1 - 10 of about 92   

Articles published

PSTI 2.83 -0.03 (-1.05%)
price chart
Pluristem Therapeutics, Inc. (PSTI) in Focus: Stock Up 7.4%
Pluristem Therapeutics, Inc. was a big mover last session, as the company saw its shares rise over 7% on the day. This rally higher can be attributable to solid volume too with far more shares changing hands than in a normal session.
Pluristem Therapeutics: A Biotech Scam Promoted By A Bucket Shop
Pluristem Therapeutics Inc. (NASDAQ:PSTI) is a clinical-stage company engaged in development of cell therapy products for the treatment of life threatening diseases.
Pluristem Therapeutics (PSTI) Reports Data from Phase I/II PLX-PAD Trail  StreetInsider.com
Pluristem Announces Significant New Finding From Its Phase I/II Muscle ...  GlobeNewswire (press release)
Pluristem Therapeutics, Inc. Short Interest Disclosure
Pluristem Therapeutics, Inc. (NASDAQ:PSTI), In a major negative the short interest in Pluristem Therapeutics, Inc. shot up by 21.3% or 160,255 shares. The final shorts are 1.4% of the total floated shares. The positions increased from 752,814 shares on ...
Top Stories in Biotech This Morning: Pluristem Therapeutics, Inc, Rigel ...
This is the second regulatory approval for the company's 3D cell manufacturing process, having received approval in Germany last January.
Related articles »  
Pluristem Therapeutics Inc. (PSTI): The Bull Case For Pluristem Therapeutics
One of the problems that the technology faced was that the cell culture process created degradation in the quality of their therapeutic ability.
Related articles »  
Pluristem surges on bullish research report (PSTI)
Thinly-traded micro cap Pluristem Therapeutics (NASDAQ:PSTI) is up 11% premarket on robust volume in apparent response to a bullish report from Acceleron equity research with a price target of $21.
Pluristem Therapeutics Inc. Analyst Rating Update  Stafford Daily
Pluristem Therapeutics Inc. (PSTI) news: Pluristem's Preeclampsia Effort ...
The power of the placenta rings truer than ever in an upcoming therapeutic indication planned by Pluristem Therapeutics, Inc. (NASDAQ:PSTI) using PLX cell therapy for treating pregnant women with preeclampsia, a leading cause of maternal and infant ...
Related articles »  
Pluristem Therapeutics Inc. (PSTI): Mesoblast Is No Match For Pluristem's IP ...
Last week, Pluristem Therapeutics Inc. (NASDAQ:PSTI) won a method of use patent in Australia for its PLX cells in ischemia, where obstruction of blood vessels to an organ causes tissue death.
Related articles »  
Will Pluristem Therapeutics (PSTI) Crush Estimates at Its Next Earnings Report?
After all, the Zacks Earnings ESP compares the most accurate estimate to the broad consensus, looking to find stocks that have seen big revisions as of late, suggesting that analysts have recently become more bullish on the company's earnings prospects.
Related articles »  
Pluristem Therapeutics Inc.: Wichtige Erkenntnisse bei einer Studie der US ...
HAIFA, ISRAEL, 19. Februar 2015 (GLOBE NEWSWIRE) -- Pluristem Therapeutics Inc. (Nasdaq:PSTI) (TASE:PSTI), ein f�hrender Entwickler von plazentabasierten Zelltherapieprodukten, gab heute die Ergebnisse einer k�rzlich abgeschlossenen Studie ...